The present invention relates to novel heteroaryl compounds of Formula (I) and their pharmaceutically acceptable salts, solvates, polymorphs, tautomers, atropisomers, optical and geometric isomers, prodrugs, or deuterated compounds including other possible isotopes thereof as inhibitors of PKMYT1 The present invention also provides the process of preparation of compounds of Formula (I) for treating cancer.
[EN] HETEROARYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE ET UTILISATIONS ASSOCIÉES
申请人:CELGENE AVILOMICS RES INC
公开号:WO2014144737A1
公开(公告)日:2014-09-18
The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.
Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases
申请人:Celgene CAR LLC
公开号:US10065966B2
公开(公告)日:2018-09-04
The present invention provides compounds of formula I-h:
useful as inhibitors of protein kinases, pharmaceutically acceptable compositions thereof, and methods of using the same.